Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

← catalyst calendar

NCT03470922 · results posted

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
714actual
Sites
127
Countries
Argentina, Australia, Austria +22

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-04-11actualWhen the study began enrolling
Primary completion2021-01-25actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2030-12-15estimatedThe whole study's end, after follow-up
First posted2018-03-20actualWhen this record first appeared on the registry
Results posted2022-03-29actualWhen the sponsor posted results to the registry
Record updated2025-09-09actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Melanoma

Interventions

  • Biological: Relatlimab
  • Biological: Nivolumab

Primary outcome

what the primary-completion date above is the date OF
Progression Free Survival (PFS)
measured From randomization to date of first documented tumor progression or death (up to approximately 33 months)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2020-11-23 · 30.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-10-25 · 838 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed